Global Business and Financial News, Stock Quotes, and Market Data and Analysis
© 2012 CNBC LLC. All Rights Reserved
© 2012 CNBC LLC. All Rights Reserved
Shares in French drugmaker Sanofi rise 2.8 percent to a fresh 7-year high, making them one of the biggest gainers among European blue chips, as traders cite speculation the group could soon get a positive recommendation from European regulators for its multiple sclerosis pill Aubagio.
"The recent rally might be because of the monthly meeting of experts from the European Medicine Agency, which is currently happening in London. Aubagio is supposed to receive a recommendation from these experts in the first quarter," a Paris-based trader says.
"Aubagio's approval in Europe would represent 200 million euros ($257.7 million) in terms of peak sales, but it would certainly increase confidence in the entire multiple sclerosis franchise, with Lemtrada due to be accepted in the second quarter in Europe and in the second half of the year in the United States."
Sanofi adds the most points to the pan-European FTSEurofirst 300 index , while rival healthcare stocks Novartis and Roche also advance by 1.7 and 1 percent respectively.
Sanofi officials were not immediately available for comment. Reuters Messaging: blaise.robinson.thomsonreuters.com@reuters.net
Reuters Messaging: sudip.kargupta.thomsonreuters.com@reuters.net ($1 = 0.7760 euros)
Keywords: MARKETS EUROPE STOCKSNEWS
© 2012 CNBC LLC. All Rights Reserved
Highlight transcript below to create clipTranscript: Print | Email Go Click text to jump within videoWed 02 Jan 13 | 10:03 AM ET CNBC's Jackie DeAngelis explains how the "fiscal cliff" deal will impact the health care sector in the long-term. And, Jonathan Bush, Athenahealth chairman, CEO & president, provides perspective on health care reform and the 'cliff' deal.
Bluesense theme designed by Make Money Online | Dosh Dosh
Bloggerized by Free Blogger Template